Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Seung-jung Park, MD
Cardiology, Asan Medical Center Heart Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Queen Mary Hospital
Hong Kong, Hong Kong
- Asan Medical Center
Seoul, Songpa-gu, South Korea
- Bundang Cha Hospital
Seongnam, South Korea
- Cheng Hsin General Hospital
Taipei, Taiwan
- National Taiwan University Hospital
Taipei, Taiwan
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Mar 2018
- Primary completion
- 26 Oct 2021
- Completion
- 5 Nov 2021
- Last update posted
- 8 Nov 2021
- Registered enrollment
- 235
- Registry id
- NCT03284827
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.